PathWhiz ID | Pathway | Meta Data |
---|---|---|
PW145934View Pathway |
drug action
Tedizolid phosphate Drug Metabolism Action PathwayHomo sapiens
|
Creator: Ray Kruger Created On: October 07, 2023 at 17:00 Last Updated: October 07, 2023 at 17:00 |
PW176143View Pathway |
Tedizolid Predicted Metabolism Pathway newHomo sapiens
Metabolites of Tedizolid are predicted with biotransformer.
|
Creator: Omolola Created On: November 29, 2023 at 14:17 Last Updated: November 29, 2023 at 14:17 |
PW146050View Pathway |
drug action
Tegafur Drug Metabolism Action PathwayHomo sapiens
|
Creator: Ray Kruger Created On: October 07, 2023 at 17:17 Last Updated: October 07, 2023 at 17:17 |
PW146093View Pathway |
drug action
Tegafur-uracil Drug Metabolism Action PathwayHomo sapiens
|
Creator: Ray Kruger Created On: October 07, 2023 at 17:23 Last Updated: October 07, 2023 at 17:23 |
PW145170View Pathway |
drug action
Tegaserod Drug Metabolism Action PathwayHomo sapiens
|
Creator: Ray Kruger Created On: October 07, 2023 at 15:14 Last Updated: October 07, 2023 at 15:14 |
PW127444View Pathway |
drug action
Teicoplanin Action PathwayStaphylococcus aureus
Teicoplanin is a glycopeptide antibiotic with a similar mechanism of action and spectrum of activity to vancomycin used to treat various infections caused by gram-positive bacteria. It is used for the treatment of bacterial infections caused by susceptible microorganisms.
It is a glycopeptide antiobiotic extracted from Actinoplanes teichomyceticus, with a similar spectrum of activity to vancomycin. Its mechanism of action is to inhibit bacterial cell wall synthesis. Teicoplanin inhibits peptidoglycan polymerization, resulting in inhibition of bacterial cell wall synthesis and cell death.
Oral teicoplanin has been demonstrated to be effective in the treatment of pseudomembranous colitis and Clostridium difficile-associated diarrhoea, with comparable efficacy to vancomycin.
Teicoplanin is poorly absorbed after oral administration but is 90% bioavailable when administered intramuscularly.
|
Creator: Karxena Harford Created On: February 10, 2023 at 11:53 Last Updated: February 10, 2023 at 11:53 |
PW145661View Pathway |
drug action
Teicoplanin Drug Metabolism Action PathwayHomo sapiens
|
Creator: Ray Kruger Created On: October 07, 2023 at 16:19 Last Updated: October 07, 2023 at 16:19 |
PW127527View Pathway |
drug action
Telaprevir Action PathwayHomo sapiens
Telaprevir is an NS3/4A viral protease inhibitor used in combination with other antivirals for the curative treatment of chronic Hepatitis C Virus infections.
Hepatitis C virus lipoviroparticles enter target hepatocytes via receptor-mediated endocytosis. The lipoviroparticles attach to LDL-R and SR-B1, and then the virus binds to CD81 and subsequently claudin-1 and occludin, which mediate the late steps of viral entry. The virus is internalized by clathrin-dependent endocytosis. RNA is released from the mature Hepatitis C virion and translated at the rough endoplasmic reticulum into a single Genome polyprotein.
Paritaprevir accumulates in the liver after uptake into hepatocytes via solute carrier organic anion transporter family member 1B1. Paritaprevir inhibits NS3/4A protease, which is an enzyme that cleaves the heptatitis C virus polyprotein downstream of the NS3 proteolytic site, which generates nonstructural proteins NS3, NS4A, NS4B, NS5A, and NS5B. These proteins are required in viral RNA replication, therefore because of the inhibition of their formation, RNA replication cannot occur. Because RNA replication does not occur, the mature virion is unable to form.
At higher concentration above their antiviral half-maximal effective concentration (EC50), Paritaprevir and other NS3/4A inhibitors also restore interferon (IFN)-signaling pathways that are thought to be disrupted by NS3/4A protease and recover innate immune processes. NS3/4A protease cleaves two essential adaptor proteins that initiate signaling leading to activation of IFN regulatory factor 3 and IFN-α/β synthesis, which are mitochondrial antiviral-signaling proteins.
|
Creator: Ray Kruger Created On: April 06, 2023 at 16:25 Last Updated: April 06, 2023 at 16:25 |
PW145645View Pathway |
drug action
Telaprevir Drug Metabolism Action PathwayHomo sapiens
|
Creator: Ray Kruger Created On: October 07, 2023 at 16:17 Last Updated: October 07, 2023 at 16:17 |
PW176144View Pathway |
Telaprevir Predicted Metabolism Pathway newHomo sapiens
Metabolites of Telaprevir are predicted with biotransformer.
|
Creator: Omolola Created On: November 29, 2023 at 14:17 Last Updated: November 29, 2023 at 14:17 |